Arbutus Biopharma Corp (NAS:ABUS)
$ 4.04 -0.01 (-0.25%) Market Cap: 762.68 Mil Enterprise Value: 624.18 Mil PE Ratio: 0 PB Ratio: 6.22 GF Score: 51/100

Q4 2023 Arbutus Biopharma Corp Earnings Call Transcript

Feb 29, 2024 / 01:45PM GMT
Release Date Price: $2.8 (-2.78%)
Operator

Good day, and thank you for standing by. Welcome to the Arbutus fourth quarter corporate And financial update conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

Lisa Caperelli
Arbutus Biopharma Corp - VP of IR

I would now like to hand the conference over to your first speaker today, Lisa Caperelli, VP of Investor Relations. Please go ahead.

Thank you, Steven, and good morning, everyone, and thank you for joining Arbutus' Fourth Quarter and Year End 2023 financial results and corporate update call. Joining me today from the Arbutus executive team are Mike McElhaugh, Interim President and Chief Executive Officer; Dr.Karen Sims, Chief Medical Officer; David Hastings, Chief Financial Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Mike McElhaugh will begin with a corporate update, followed by Karen, who will review our ongoing clinical programs. Dave will then provide a review of the company's fourth quarter And year end 2023 financial results. After our prepared remarks, we will open the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot